Laddar...
A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis
PURPOSE: Capecitabine 1,000 mg/m(2) bid × 14 days every 21 days (14/21) has been reported to have similar efficacy but more favorable toxicity profile than the approved dosage of 1,250 mg/m(2). However, a dose-toxicity relationship of capecitabine in breast cancer patients has not been fully elucida...
Sparad:
| I publikationen: | Breast Cancer Res Treat |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2016
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4988831/ https://ncbi.nlm.nih.gov/pubmed/26988358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3756-5 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|